Genmab, Immunex, Medarex deal

Genmab received exclusive worldwide rights to develop antibodies against IL-15, a cytokine implicated in a variety of inflammatory conditions. The rights were obtained from IMNX through a sublicense from MEDX, which formed Genmab in March to develop human antibodies derived from MEDX's HuMAb-Mouse technology (see BioCentury, March 8). Genmab also received a license to an additional undisclosed target from MEDX in exchange for $2 million in Genmab equity. ...